Fineline Cube

Follow:
14610 Articles
Suzhou Rigerna Therapeutics' RG002C0106 Injection Supplemental Application Accepted by China's CDE – Class 1 Chemical Drug Enters Regulatory Review
CompanyDrug

Suzhou Rigerna Therapeutics’ RG002C0106 Injection Supplemental Application Accepted by China’s CDE – Class 1 Chemical Drug Enters Regulatory Review

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot
CompanyDrug

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for Advanced Prostate Cancer – GenSci to Commercialize the 6‑Month Leuprolide Depot

InnoCare's TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease
CompanyDrug

InnoCare’s TL1A/IL‑23p19 Bispecific Antibody ICP‑B161 Cleared for Clinical Trials – Fifth Innovative Drug IND of 2026 Targets Inflammatory Bowel Disease

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled
CompanyDrug

Kangtai Biological Products Initiates Phase I Trial of Adult, Adolescent and Pediatric Acellular Pertussis‑Diphtheria‑Tetanus (Component) Combination Vaccine – First Subject Enrolled

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus
CompanyDrug

China Resources Double‑Crane Subsidiary Clears FDA for DC7001A Capsules – Investigational Therapy Advances Toward Clinical Trials in Systemic Lupus Erythematosus

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise
CompanyDrug

China Resources Double‑Crane Subsidiary Secures NMPA Approval for Vortioxetine Hydrobromide API – Vertically Integrating Its Antidepressant Franchise

AstraZeneca and Daiichi Sankyo's Enhertu Wins NMPA Approval in HER2‑Positive Early Breast Cancer – New Adjuvant Indication and Full Approval of Neoadjuvant Label in China
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Wins NMPA Approval in HER2‑Positive Early Breast Cancer – New Adjuvant Indication and Full Approval of Neoadjuvant Label in China

Hansoh Pharmaceutical Resubmits Aumuletinib MAA to the EMA – EGFR‑TKI Application Validated for Two Advanced NSCLC Indications After EU Market Withdrawal
CompanyDrug

Hansoh Pharmaceutical Resubmits Aumuletinib MAA to the EMA – EGFR‑TKI Application Validated for Two Advanced NSCLC Indications After EU Market Withdrawal

Edding Genor's GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer
CompanyDrug

Edding Genor’s GB268 Wins NMPA IND Approval for Phase II Trial – PD‑1/CTLA‑4/VEGF Trispecific Antibody Plus Chemotherapy Targets First‑Line Advanced Colorectal Cancer

Sichuan Biokin's Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC
CompanyDrug

Sichuan Biokin’s Iza‑Bren Combination Therapy Clinical Trial Application Approved by NMPA – EGFR×HER3 Bispecific ADC Advances with Radiotherapy in Locally Advanced Unresectable HNSCC

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer
CompanyDrug

Transcenta Granted Chinese Invention Patent for Anti‑CLDN18.2 Antibodies – Protecting the Companion Diagnostic for Osemitamab (TST001) in Gastric Cancer